Official websites use .gov
Secure .gov websites use HTTPS
« Previous
Next »
Titles
- Buprenorphine: an overview for clinicians1
- Catalyzing Medicaid policy research with T-MSIS Analytic Files (TAF): learnings from year 1 of the Medicaid Data Learning Network (MDLN)1
- Dear Doctor, I wish to call your attention to our remedy, Manine, for the treatment and cure of that diseased condition of the nervous system caused by the use of morphine, laudanum, heroin or opium in any of its forms1
- Early changes in waivered clinicians and utilization of buprenorphine for opioid use disorder after implementation of the 2021 HHS Buprenorphine Practice Guidelines1
- Expanding access to naloxone: a review of distribution strategies1
- Extended-release opioid agonists and antagonist medications for addiction treatment (MAT) in patients with opioid use disorder: effectiveness and value : final evidence report1
- Geographic disparities affect access to buprenorphine services for opioid use disorder1
- How community health centers are addressing the opioid epidemic: case study1
- Increasing access to medications for opioid use disorder: policy strategies during and after COVID-19 pandemic1
- Learning from COVID-19: how pandemic-era policies for methadone prescribing could improve opioid treatment1
- Lowering the barriers to medication treatment for people with opioid use disorder: evidence for a low-threshold approach1
- MAT for hospitalized patients1
- MAT for opioid use disorder: overcoming objections1
- MAT in community health centers1
- MAT in the emergency department: FAQ1
- Management of patients with opioid dependence: a review of clinical, delivery system, and policy options1
- Many Medicaid enrollees with opioid use disorder were treated with medication: however, disparities present concerns1
- Medical profession endorse Manine in the treatment of morphinism or the drug "habit" disease1
- Opioid use decreased in Medicare Part D, while medication-assisted treatment increased1
- Opioid use disorder: barriers to Medicaid beneficiaries' access to treatment medications : report to Congressional committees1